BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/14/2021 11:58:13 PM | Browse: 434 | Download: 1159
 |
Received |
|
2021-02-15 14:44 |
|
Peer-Review Started |
|
2021-02-15 14:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-15 04:54 |
|
Revised |
|
2021-03-24 20:55 |
|
Second Decision |
|
2021-10-15 06:33 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-10-15 09:02 |
|
Articles in Press |
|
2021-10-15 09:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-09-29 19:20 |
|
Typeset the Manuscript |
|
2021-12-07 04:32 |
|
Publish the Manuscript Online |
|
2021-12-14 23:58 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Saleh A Alqahtani and Massimo G Colombo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Massimo G Colombo, MD, Professor, Liver Center, IRCCS San Raffaele Hospital, Via Olgettina 60, Milan 20132, Italy. mcolombo46@yahoo.it |
| Key Words |
Hepatocellular carcinoma; Immune checkpoint inhibitor; Lenvatinib; Multi-tyrosine kinase inhibitor; Sorafenib |
| Core Tip |
Recently, an immunotherapy-based combination of atezolizumab and bevacizumab was shown to prolong survival compared to sorafenib in unresectable hepatocellular carcinoma (HCC) patients who did not receive prior therapy. In addition, the combination of lenvatinib and pembrolizumab has yielded promising results in the same patient setting. This review article summarizes the results obtained with sorafenib and lenvatinib in patients with unresectable HCC in pivotal clinical trials and real-world studies. We offer guidance on the optimal choice between sorafenib or lenvatinib in an individual patient and discuss the immunotherapy-based combination, which will likely make the choice between sorafenib and lenvatinib somewhat obsolete. |
| Publish Date |
2021-12-14 23:58 |
| Citation |
Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(12): 2038-2049 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i12/2038.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i12.2038 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
